Nothing says “we’ve got this” like pulling your nominee the day before the committee votes. The White House has dropped Dr. Heidi Overton as its nominee to run the FDA, a day before the Senate health committee was set to vote on her. The Axios scoop says she lacked the support on Capitol Hill to be confirmed. The news instantly changes who runs the agency behind roughly 20% of U.S. consumer spending, per CBS, and that touches your food, your medicine and your kids’ vaccines.
CNN, CBS, NBC, ABC and the AP each report that a White House official confirmed the move. A senior administration official told Axios that Overton “lacks the support on the Hill to move forward with her confirmation.” That is the administration’s version, not a neutral finding. Committee chair Sen. Bill Cassidy pushed back right away, saying he was still undecided.

What happened to the FDA nomination
Overton is a physician and deputy director of the White House Domestic Policy Council. Trump announced her pick on Truth Social on Aug. 19, and she testified before the Senate HELP Committee on Sept. 24. The committee vote was scheduled for Wednesday, Nov. 18. Now it is moot. Other nominees on the same agenda are still in line, including Jim O’Neill for National Science Foundation director, according to CNN.
The math was tight. Republicans hold a one-vote majority on the committee. None of its Democrats were expected to back her, per CBS News. If every Democrat said no, a single Republican defection would sink her.
Why the Senate balked at the FDA nominee
Objections came from every direction. Cassidy, a Louisiana Republican and a physician, criticized her role in Trump’s executive order on the childhood vaccine schedule. He previously called her support for breaking up combination vaccines, including MMR, “almost disqualifying.” He also cited her “lack of managerial experience,” according to MS NOW.
Other Republicans had their own issues. Sen. Susan Collins raised concerns about flavored e-cigarettes. Sen. Lisa Murkowski criticized her for not taking a clear position on mifepristone, the abortion pill. Antiabortion groups also questioned whether she would tighten prescribing rules, which gave the FDA nominee trouble on yet another front.
Then there is the twist: opposition came from inside the MAHA movement too. Calley Means, a recently resigned top adviser to HHS Secretary Robert F. Kennedy Jr., said on “Face the Nation” that Overton “was the biggest block to MAHA policies I encountered in the government.” That makes it a rare trifecta of left, middle and allies.
Here’s the thing: what this means for FDA leadership and you
The FDA regulates food, drugs, vaccines and vaping products. Acting Commissioner Kyle Diamantas runs the agency now, after Marty Makary resigned in May. The clock is running down on this session of Congress, so Diamantas is likely to stay in charge well into 2027.
An agency with no confirmed leader still has decisions to make. Per NBC News, the FDA will finish its mifepristone safety review in March under an acting leader. The agency also recently authorized the first fruit-flavored e-cigarettes for adult smokers. It has already shown it is not idle, as when it added a vision loss warning to Ozempic, Zepbound and other GLP-1s.
Still, the FDA has lost about 20% of its employees since Trump took office, NBC Chicago reports. It is steering through all this with a thinner crew.
The fight over who sank the FDA pick
Cassidy disputed the White House’s claim that Overton lacked the votes, according to The Hill. He had said earlier Tuesday that he was undecided. CBS reports whip efforts were still underway when the White House told allies of its decision that evening. On X, Cassidy wrote that “with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats.”
That line points to the clock. Cassidy leaves Congress in early January, and Republicans are racing to confirm nominees before Democrats take over the Senate. Time is short, and a new nominee would have to start from scratch.
What happens next for the FDA nomination
CBS reports the White House has begun looking for a new candidate. It has spoken with potential picks, including some who could serve in an acting capacity and skip Senate confirmation. CBS also says Sen. Roger Marshall, a Kansas Republican and a doctor, is making a play for the job. The AP says it is not clear when the White House will name another nominee.
This is also the latest HHS-area nomination to fall apart. The White House withdrew Casey Means’s nomination in April, and earlier picks stalled in 2025. If you were hoping for a quick answer on who steers the FDA, don’t hold your breath.
Meanwhile, the agency keeps shaping what lands in your life, from weight-loss drugs like Wegovy to the energy drinks tied to cardiac arrest reports. The mifepristone review is due in March, and a fill-in is at the wheel. Who signs off on it?






